Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in ... has shown a clinical benefit in ...

Under the terms of the agreement, Immuneering will sponsor the planned studies, while Regeneron will provide Libtayo ... in its ongoing Phase 2a clinical trials involving IMM-1-104, a treatment ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Libtayo. The deal supports a Phase 2a clinical trial evaluating Immuneering's lead drug, IMM-1-104, in combination with Libtayo for RAS-mutant non-small cell lung cancer (NSCLC). Regeneron's stock ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety ... in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...